Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus

Published:2023-10 Issue:5 Volume:17 Page:460-465
ISSN:1751-9918
Container-title:Primary Care Diabetes
language:en
Short-container-title:Primary Care Diabetes

Author:

Lee Jeongmin^ORCID,Kim Raeun,Kim Min-Hee,Lee Seung-Hwan,Cho Jae-Hyoung,Lee Jung Min,Jang Sang-Ah^ORCID,Kim Hun-Sung

Publisher

Elsevier BV

Subject

Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine,Family Practice

Reference35 articles.

1. World Health Organization, Obesity and overweight, 2021. Available at: 〈https://www-who-int-ssl.proxy.cuk.ac.kr/news-room/fact-sheets/detail/obesity-and-overweight〉. (Accessed 7 April 2022).

2. Fact Sheet of the Korean Society for the Study of Obesity, Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018;Nam;J. Obes. Metab. Syndr.,2021

3. Morbidity and mortality associated with obesity;Abdelaal;Ann. Transl. Med.,2017

4. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021;American Diabetes Association;Diabetes Care,2021

5. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial;Davies;JAMA,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty;The Journal of Arthroplasty;2024-05

2. Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists;International Journal of Molecular Sciences;2024-04-30

3. SIBUTRAMINA E LIRAGLUTIDA NA TERAPÊUTICA DA OBESIDADE;Revista Contemporânea;2024-04-22